Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 5/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 4/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 7/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.41 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.41 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13810662 | 0.85 | KDR (0.49) | MET | |
| SCHEMBL13810670 | 0.85 | MET (0.48) | CLK1CHEK1CHEK2MET | |
| SCHEMBL1953680 | 0.83 | MET (0.52) | CLK1METKMT2A | |
| SCHEMBL13810667 | 0.81 | KDR (0.53) | MET | |
| SCHEMBL13810665 | 0.78 | SMN1; SMN2 (0.48) | METMEN1KMT2A | |
| SCHEMBL1657795 | 0.74 | MET (0.63) | CLK1METCSF1R | |
| SCHEMBL5990507 | 0.73 | CLK1 (0.51) | CLK1METMAPK8NTRK1NTRK2 | |
| SCHEMBL29074140 | 0.69 | CSF1R (0.46) | CLK1METMAPK8CSF1RNTRK1 | |
| SCHEMBL17754814 | 0.68 | GRIN1 (0.63) | METCSF1RNTRK1NTRK3NTRK2 | |
| SCHEMBL12821543 | 0.68 | MET (0.57) | METMAPK8CSF1RNTRK1NTRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156617-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2009-06-18 | — | — | US | disclosed |
| US-20090156617-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156617-A1 | Tyrosine kinase inhibitors | ABL1, ERBB2, MET | CLK1 890/4885CHEK1 384/4885CHEK2 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.